It was documented that VEGFA-amplified mouse HCC were more sensitive to sorafenib, and HCC patients with a VEGFA gain showed markedly improved survival upon sorafenib treatment compared to non-VEGFA-gain patients [42]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.